New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - iron polymaltose 50 mg/ml (318mg iron polymaltose equivalent to 100mg iron iii) - solution for injection - 50 mg/ml - active: iron polymaltose 50 mg/ml (318mg iron polymaltose equivalent to 100mg iron iii) excipient: hydrochloric acid sodium hydroxide water for injection

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية صادق - sadeq drug store - iron 50 mg/ml - 50 mg/ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 208 mg/ml - eq. iron (iii) 50 mg/ml - solution for injection - 50 mg/ml - iron (iii) isomaltoside 1000 208 mg/ml; iron (iii) ions 50 mg/ml - iron, parenteral preparations

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets are indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. spironolactone tablets are usually administered in conjunction with other heart failure therapies. spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one dru

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 50 mg - spironolactone tablets are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure : for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate.  cirrhosis of the liver accompanied by edema and/or ascites : aldosterone levels may be exceptionally hi

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron carboxymaltose 180 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - 50 mg/ml - ferric carboxymaltose 180 mg/ml - iron, parenteral preparations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron carboxymaltose 180 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - 50 mg/ml - ferric carboxymaltose 180 mg/ml - iron, parenteral preparations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron carboxymaltose 180 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - 50 mg/ml - ferric carboxymaltose 180 mg/ml - iron, parenteral preparations

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association's diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du